newsfilter
← Latest News
Business Wire·

Dyax Corp. Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology Annual Meeting

BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today announced that two oral presentations describing clinical data from its DX-2930 Phase 1b study were presented at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Meeting taking place in San Antonio, Texas. DX-2930 is an investigational fully human monoclonal antibody inhibitor of plasma kallikrein (pKal) being developed for the prevention of hereditary angioedema (HAE) attacks.